Contrasting Izotropic (OTCMKTS:IZOZF) and DermTech (NASDAQ:DMTK)

Izotropic (OTCMKTS:IZOZF) and DermTech (NASDAQ:DMTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Izotropic and DermTech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Izotropic	0	0	0	0	N/A
DermTech	0	1	3	0	2.75

DermTech has a consensus target price of $6.33, suggesting a potential upside of 226.46%. Given DermTech’s higher probable upside, analysts clearly believe DermTech is more favorable than Izotropic.

Profitability

This table compares Izotropic and DermTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Izotropic	N/A	N/A	N/A
DermTech	-853.02%	-99.14%	-65.52%

Earnings and Valuation

This table compares Izotropic and DermTech’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Izotropic	N/A	N/A	N/A	N/A	N/A
DermTech	$14.02 million	4.66	-$116.68 million	($3.90)	-0.50

Izotropic has higher earnings, but lower revenue than DermTech.

Institutional and Insider Ownership

27.8% of DermTech shares are held by institutional investors. 5.1% of DermTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

DermTech beats Izotropic on 5 of the 8 factors compared between the two stocks.

About Izotropic

Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

About DermTech

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.